-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Arrowhead Pharmaceuticals, Inc. quarterly/annual Earnings Per Share, Diluted history and growth rate from 2010 to 2024.
- Arrowhead Pharmaceuticals, Inc. Earnings Per Share, Diluted for the quarter ending September 30, 2024 was -1.36 USD/shares, a 33.3% decline year-over-year.
- Arrowhead Pharmaceuticals, Inc. Earnings Per Share, Diluted for the twelve months ending September 30, 2024 was -5 USD/shares, a 160% decline year-over-year.
- Arrowhead Pharmaceuticals, Inc. annual Earnings Per Share, Diluted for 2024 was -5 USD/shares, a 160% decline from 2023.
- Arrowhead Pharmaceuticals, Inc. annual Earnings Per Share, Diluted for 2023 was -1.92 USD/shares, a 15% decline from 2022.
- Arrowhead Pharmaceuticals, Inc. annual Earnings Per Share, Diluted for 2022 was -1.67 USD/shares, a 22.8% decline from 2021.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Annual (USD/shares)
Earnings Per Share, Diluted, YoY Annual Growth (%)